Adverum Biotechnologies (ADVM)

• Market cap: $89M
• 1 day: 4.18%
• 5 days: -5.15%
• 1 month: -7.83%
• 3 months: 60%
• 6 months: 47.22%
• Year to date: -11.67%
• 1 year: -46.46%
• 5 years: -96.52%
• 10 years: -94.72%
• Sector: Healthcare
• Industry: Biotechnology

About: Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

Employees: 155